BioCentury | Jan 15, 2021
Finance

A maturing mid-cap sector could keep funds flowing into biotech

...will be there for companies to consume.” Parkman Healthcare Partners’...
...people than ever before.” Greg Martinez, Parkman Healthcare Partners...
BioCentury | Jan 12, 2021
Finance

Jan. 11 Quick Takes: Megarounds for Valo, Visen; plus NuProbe, Sensei

...endocrinology therapies in Greater China. Sequoia China led the round with participation from OrbiMed Advisors, Sherpa Healthcare Partners...
BioCentury | Jan 12, 2021
Management Tracks

Editas shares sink as CSO Albright readies to depart; plus Arcutis, Precirix, Frazier

...by Novartis AG (NYSE:NVS; SIX:NOVN). She is the first U.S. hire for the Belgian company.Frazier Healthcare Partners...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...takes 50% stake in cold chain shipping companyPE firm Thomas H. Lee Partners granted Frazier Healthcare Partners...
BioCentury | Dec 12, 2020
Finance

Forbion to focus record €460M fund on early-stage opportunities

...two other European life sciences VCs — LSP and Gilde Healthcare Partners ...
BioCentury | Nov 20, 2020
Finance

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

...series C financing led by Farallon Capital Management LLC. Existing investors Blackstone Life Sciences, Frazier Healthcare Partners...
BioCentury | Nov 14, 2020
Emerging Company Profile

Ex-Mavupharma execs reunite at Inipharm to build liver disease pipeline

...and Wu Capital joined existing investors Frazier Healthcare Partners...
...focus: HepaticClinical status: PreclinicalFounded: 2018 by Frazier Healthcare Partners...
...of employees: 6Funds raised: $43 millionInvestors: Frazier Healthcare Partners...
BioCentury | Nov 3, 2020
Finance

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

...HKEX:2359) launched JW in 2016 to develop immuno-oncology cell therapies for cancer patients in China.Fountain Healthcare Partners...
...Fund III at €125MWith plans to invest in up to 10 private life science companies, Fountain Healthcare Partners...
...5A BC Staff LUMEVOQ (GS010, RAAV2/2_ND4) Avacopan (CCX168, C5aR inhibitor) JW Therapeutics Co. Ltd. GenSight Biologics S.A. Vifor Pharma Ltd. ChemoCentryx Inc. Fountain Healthcare Partners...
BioCentury | Oct 14, 2020
Management Tracks

Ex-Sanofi CMO Nathwani to lead Dewpoint; plus Inozyme, ReCode and Frazier

...to pair RNA therapeutics for rare respiratory diseases with an organ-specific lipid nanoparticle delivery technology.Frazier Healthcare Partners...
...preclinical functions, clinical pharmacology and the scientific arm of BD. Jeff Cranmer Dewpoint Therapeutics Inozyme Pharma Inc. ReCode Therapeutics Frazier Healthcare Partners Ameet...
BioCentury | Oct 12, 2020
Finance

Priothera raises €30 million to develop onetime Novartis candidate in AML transplantation setting

...a single-asset company with staff from Novartis who had already worked on the program, Fountain Healthcare Partners’...
Items per page:
1 - 10 of 327
BioCentury | Jan 15, 2021
Finance

A maturing mid-cap sector could keep funds flowing into biotech

...will be there for companies to consume.” Parkman Healthcare Partners’...
...people than ever before.” Greg Martinez, Parkman Healthcare Partners...
BioCentury | Jan 12, 2021
Finance

Jan. 11 Quick Takes: Megarounds for Valo, Visen; plus NuProbe, Sensei

...endocrinology therapies in Greater China. Sequoia China led the round with participation from OrbiMed Advisors, Sherpa Healthcare Partners...
BioCentury | Jan 12, 2021
Management Tracks

Editas shares sink as CSO Albright readies to depart; plus Arcutis, Precirix, Frazier

...by Novartis AG (NYSE:NVS; SIX:NOVN). She is the first U.S. hire for the Belgian company.Frazier Healthcare Partners...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...takes 50% stake in cold chain shipping companyPE firm Thomas H. Lee Partners granted Frazier Healthcare Partners...
BioCentury | Dec 12, 2020
Finance

Forbion to focus record €460M fund on early-stage opportunities

...two other European life sciences VCs — LSP and Gilde Healthcare Partners ...
BioCentury | Nov 20, 2020
Finance

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

...series C financing led by Farallon Capital Management LLC. Existing investors Blackstone Life Sciences, Frazier Healthcare Partners...
BioCentury | Nov 14, 2020
Emerging Company Profile

Ex-Mavupharma execs reunite at Inipharm to build liver disease pipeline

...and Wu Capital joined existing investors Frazier Healthcare Partners...
...focus: HepaticClinical status: PreclinicalFounded: 2018 by Frazier Healthcare Partners...
...of employees: 6Funds raised: $43 millionInvestors: Frazier Healthcare Partners...
BioCentury | Nov 3, 2020
Finance

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

...HKEX:2359) launched JW in 2016 to develop immuno-oncology cell therapies for cancer patients in China.Fountain Healthcare Partners...
...Fund III at €125MWith plans to invest in up to 10 private life science companies, Fountain Healthcare Partners...
...5A BC Staff LUMEVOQ (GS010, RAAV2/2_ND4) Avacopan (CCX168, C5aR inhibitor) JW Therapeutics Co. Ltd. GenSight Biologics S.A. Vifor Pharma Ltd. ChemoCentryx Inc. Fountain Healthcare Partners...
BioCentury | Oct 14, 2020
Management Tracks

Ex-Sanofi CMO Nathwani to lead Dewpoint; plus Inozyme, ReCode and Frazier

...to pair RNA therapeutics for rare respiratory diseases with an organ-specific lipid nanoparticle delivery technology.Frazier Healthcare Partners...
...preclinical functions, clinical pharmacology and the scientific arm of BD. Jeff Cranmer Dewpoint Therapeutics Inozyme Pharma Inc. ReCode Therapeutics Frazier Healthcare Partners Ameet...
BioCentury | Oct 12, 2020
Finance

Priothera raises €30 million to develop onetime Novartis candidate in AML transplantation setting

...a single-asset company with staff from Novartis who had already worked on the program, Fountain Healthcare Partners’...
Items per page:
1 - 10 of 327